Financials
Financial year 2025
S.H. Respiratory Medicine from Sint-Genesius-Rode, company number BE0746533378, closed financial year 2025 with a result of € 152,863 after tax. For that financial year S.H. Respiratory Medicine recorded a gross margin of € 200,687 and equity of € 124,318. Compared with financial year 2024, the result moved from € 50,360 to € 152,863. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 16, 2026.
€ 124,318
▲ € 94,039 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 152,863
▲ 204% vs 2024
Profit after tax over the fiscal year.
€ 134,522
▲ 77% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 58,824 paid out
38 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 3,510
▼ 27% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 1,282
▲ 59% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 6,420
▲ 33% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 49,465 | € 42,698 | € 69,574 | € 200,687 | ▲ 188% |
| Profit after taxes | € 35,205 | € 28,358 | € 50,360 | € 152,863 | ▲ 204% |
| Equity | € 51,561 | € 49,919 | € 30,279 | € 124,318 | ▲ € 94,039 |
| Total debts | € 29,610 | € 32,390 | € 75,770 | € 66,649 | ▼ 12% |
| Cash | € 72,326 | € 70,325 | € 75,890 | € 134,522 | ▲ 77% |
| Retained profit | € 47,561 | € 45,919 | € 26,279 | € 120,318 | ▲ € 94,039 |
| Dividend | € 25,000 | € 30,000 | € 70,000 | € 58,824 | ▼ 16% |
| Balance sheet total | € 81,171 | € 82,309 | € 106,049 | € 190,967 | ▲ 80% |
Key figures of S.H. Respiratory Medicine, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to S.H. Respiratory Medicine?
What happened at S.H. Respiratory Medicine in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 152,863 (▲ 204% vs 2024). Source: NBB ↗
- New establishment in Sint-Genesius-Rode. KBO
- New establishment in Sint-Genesius-Rode. KBO
- New establishment in Oudergem. KBO
- Sophie HARDY became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 35,205 profit in 2022 to € 152,863 profit in 2025.
Paid € 76,916 in corporate taxes since 2022.
Best year ever: 2025, with € 152,863 profit.
Paid out € 183,824 in dividends to the owners in total.
Management
Behind S.H. Respiratory Medicine is Sophie HARDY.
Directors
According to the 2025 annual accounts
Sophie HARDY
Director
since 2020
Establishments
Establishment units
Physical locations of this company
Maria-Joannalaan 19 box A
1640 Sint-Genesius-Rode
Triomflaan 201
1160 Oudergem
Active since 1 May 2020
Waterloose Steenweg 210
1640 Sint-Genesius-Rode
Active since 1 April 2023
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0746.533.378
- VAT number
- BE 0746.533.378
- Registered office
- Maria-Joannalaan 19 bus A, 1640 Sint-Genesius-Rode
- Names & denominations
- S.H. Respiratory Medicine
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 27 April 2020
- Peppol
- Active · Active since 3 Jan 2026
- Activities · NACE
Activiteiten van medisch specialisten
Overige zakelijke dienstverlening, neg
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies